Clinical Trials Logo

Clinical Trial Summary

The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.


Clinical Trial Description

The trial is randomized (1:1 alirocumab to placebo), double-blinded, placebo-controlled with a cross-over design. The trial will last 10 months and includes a 10 week washout period between study phases.Twenty adult subjects with dyslipidemia secondary to nephrotic syndrome and treated with atorvastatin will be recruited. Alirocumab or placebo will be co-administered biweekly. Safety, efficacy chemistries, vital signs, anthropometry and monitoring for adverse events also will done at each visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03004001
Study type Interventional
Source Dallas VA Medical Center
Contact
Status Terminated
Phase Phase 2
Start date January 2017
Completion date December 2019

See also
  Status Clinical Trial Phase
Completed NCT02238418 - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Phase 4
Completed NCT01895894 - Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome Phase 4
Completed NCT01411982 - Role of PACAP in Nehprotic Syndrome N/A
Recruiting NCT00308321 - Long Term Tapering or Standard Steroids for Nephrotic Syndrome Phase 4
Active, not recruiting NCT03326037 - Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Completed NCT01252901 - Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases N/A
Completed NCT01197040 - Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome Phase 3
Terminated NCT00883636 - Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis N/A
Completed NCT00035334 - Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Phase 2/Phase 3
Terminated NCT00004466 - Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome Phase 2
Terminated NCT04558892 - Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome. Phase 2/Phase 3
Completed NCT02257697 - A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome Phase 3
Completed NCT00362531 - Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Phase 2/Phase 3
Completed NCT00289328 - Glucocorticoid-induced Osteopenia in Children N/A
Recruiting NCT04759274 - Diuretic Tuner Clinical Decision Support N/A
Completed NCT00001212 - Drug Therapy in Lupus Nephropathy Phase 2
Recruiting NCT05623033 - The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
Completed NCT03332420 - The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
Not yet recruiting NCT05904197 - Effectiveness of Educational Gamified Cards About Nephrotic Syndrome N/A